Limitations exist in identifying patients with major depressive disorder (MDD) and cognitive impairment, despite a majority of MDD patients exhibiting cognitive symptoms. Cognitive dysfunction also affects patient functional outcomes, including workforce performance and psychosocial interactions. Emerging agents, including multimodal antidepressants, show a promising direct effect on improving cognitive impairment in patients with MDD. Increased knowledge on diagnosis, treatment, long-term management, and integration of emerging treatment options into clinical practice will allow physicians to select appropriate treatment strategies and improve outcomes for patients with MDD and cognitive dysfunction.
Guy M. Goodwin, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Cephalon, Inc.; GlaxoSmithKline; Janssen-Cilag; Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Otsuka Pharmaceutical Co., Ltd.; P1vital; Roche; SERVIER; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; Teva Neuroscience, Inc.
Received grants for clinical research from: SERVIER
Owns stock, stock options, or bonds from: P1vital
Served as an expert witness for: Eli Lilly and Company
John Harrison, CSci, CPsychol, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Anavex Life Sciences Corp.; AstraZeneca Pharmaceuticals LP; Avraham Pharmaceuticals; AXON; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bracket Global; Catenion; CRF Health; Dendron UK; Eisai Co., Ltd; Eli Lilly and Company; EnVivo Pharmaceuticals; ePharmaSolutions; Heptares; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kyowa Hakko Kirin Co., Ltd.; Lundbeck, Inc.; MedAvante; Mind Agilis; MyCognition; Neurocog; Novartis Pharmaceuticals Corporation; Nutricia; Orion Corporation; Pfizer Inc; Prana Biotechnology; Pricespective; ProStrakan, Inc.; Reviva Pharmaceuticals Inc; Roche; SERVIER; Shire; TCG; TransTech Pharma; UCB Pharma, Inc.; Velacor
Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.
Employed by a commercial interest: Metis Cognition Ltd
Siegfried Kasper, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Angelini; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, L.P.; Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pfizer Inc; Pierre Fabre; Schwabe Pharmaceuticals; Sepracor Inc.; SERVIER; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Angelini; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals Products, L.P.; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pierre Fabre; Schwabe Pharmaceuticals; SERVIER; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Lundbeck, Inc.
Raymond W. Lam, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; Lundbeck, Inc.; Pfizer Inc; Takeda Pharmaceuticals North America, Inc.; The Litebook Company
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lundbeck, Inc.; Mochida; Pfizer Inc; SERVIER
Received grants for clinical research from: Bristol-Myers Squibb Company; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc; St. Jude Medical; The Litebook Company
Roger S. McIntyre, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Organon Pharmaceuticals USA Inc.; Pfizer Inc; Shire
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck, Inc.; Pfizer Inc; Shire
David J. Nutt, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Janssen Pharmaceuticals Products, L.P.; Lundbeck, Inc.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; GlaxoSmithKline; Eli Lilly and Company; Pfizer Inc; SERVIER
Received grants for clinical research from: GlaxoSmithKline; Lundbeck, Inc.